Compare Amgen, Inc. (AMGN) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares Core S&P 500 ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares Core S&P 500 ETF trades at $756.43. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | IVV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $763.10 |
52-Week Low | $271.18 | $624.65 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IVV, tracking the S&P 500, trades at $758.39, up 0.43% on the day, with a bullish technical signal from moving averages and support near $751. The index is approaching record highs, driven by AI-led tech strength and robust earnings forecasts, though RSI levels indicate potential overbought conditions. A dividend of $2.00 is scheduled for June 2026.
The outlook remains positive given strong AI-driven earnings growth and institutional optimism, with targets like 8,250 cited by Yardeni Research (July 7, 2026). Risks include Fed policy shifts, geopolitical tensions, and high valuations; investors should focus on earnings momentum amid sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
